Riparian Pharmaceuticals
Boston, US · Delaware corporation
Founders & leadership
WA
William AdamsNamed on SEC filing
MS
Michael Serrano-WuNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$500K disclosed across 1 round · 2018
▶$500KraisedOct 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$500KraisedOct 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- William AdamsExecutive Officer, Director
- Michael Serrano-WuDirector
- Offering amount
- $3M
- Amount sold
- $500K
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $317.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $2.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2013 | $538K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- How much funding has Riparian Pharmaceuticals raised?
- Riparian Pharmaceuticals has disclosed $500K raised across 1 round.
- Where is Riparian Pharmaceuticals headquartered?
- Riparian Pharmaceuticals is headquartered in Boston, US.